348 related articles for article (PubMed ID: 26383637)
21. MED12 mutations in uterine leiomyomas: prediction of volume reduction by gonadotropin-releasing hormone agonists.
Nagai K; Asano R; Sekiguchi F; Asai-Sato M; Miyagi Y; Miyagi E
Am J Obstet Gynecol; 2023 Feb; 228(2):207.e1-207.e9. PubMed ID: 36150519
[TBL] [Abstract][Full Text] [Related]
22. Frequency and Spectrum of MED12 Exon 2 Mutations in Multiple Versus Solitary Uterine Leiomyomas From Russian Patients.
Osinovskaya NS; Malysheva OV; Shved NY; Ivashchenko TE; Sultanov IY; Efimova OA; Yarmolinskaya MI; Bezhenar VF; Baranov VS
Int J Gynecol Pathol; 2016 Nov; 35(6):509-515. PubMed ID: 26630226
[TBL] [Abstract][Full Text] [Related]
23. Expression of erythropoietin messenger ribonucleic acid in wild-type MED12 uterine leiomyomas under estrogenic influence: new insights into related growth disparities.
Asano R; Asai-Sato M; Matsukuma S; Mizushima T; Taguri M; Yoshihara M; Inada M; Fukui A; Suzuki Y; Miyagi Y; Miyagi E
Fertil Steril; 2019 Jan; 111(1):178-185. PubMed ID: 30554729
[TBL] [Abstract][Full Text] [Related]
24. The study of MED12 gene mutations in uterine leiomyomas from Iranian patients.
Sadeghi S; Khorrami M; Amin-Beidokhti M; Abbasi M; Kamalian Z; Irani S; Omrani M; Azmoodeh O; Mirfakhraie R
Tumour Biol; 2016 Feb; 37(2):1567-71. PubMed ID: 26298726
[TBL] [Abstract][Full Text] [Related]
25. Lack of evidence for frequent MED12 p.L1224F mutation in prostate tumours from Caucasian patients.
Stoehr R; Taubert H; Gaisa NT; Smeets D; Kneitz B; Giedl J; Ruemmele P; Wieland WF; Rau TT; Hartmann A
J Pathol; 2013 Aug; 230(4):453-6. PubMed ID: 23661306
[TBL] [Abstract][Full Text] [Related]
26. Vitamin D as an effective treatment in human uterine leiomyomas independent of mediator complex subunit 12 mutation.
Corachán A; Trejo MG; Carbajo-García MC; Monleón J; Escrig J; Faus A; Pellicer A; Cervelló I; Ferrero H
Fertil Steril; 2021 Feb; 115(2):512-521. PubMed ID: 33036796
[TBL] [Abstract][Full Text] [Related]
27. Somatic MED12 mutations in uterine leiomyosarcoma and colorectal cancer.
Kämpjärvi K; Mäkinen N; Kilpivaara O; Arola J; Heinonen HR; Böhm J; Abdel-Wahab O; Lehtonen HJ; Pelttari LM; Mehine M; Schrewe H; Nevanlinna H; Levine RL; Hokland P; Böhling T; Mecklin JP; Bützow R; Aaltonen LA; Vahteristo P
Br J Cancer; 2012 Nov; 107(10):1761-5. PubMed ID: 23132392
[TBL] [Abstract][Full Text] [Related]
28. MED12 alterations in both human benign and malignant uterine soft tissue tumors.
Pérot G; Croce S; Ribeiro A; Lagarde P; Velasco V; Neuville A; Coindre JM; Stoeckle E; Floquet A; MacGrogan G; Chibon F
PLoS One; 2012; 7(6):e40015. PubMed ID: 22768200
[TBL] [Abstract][Full Text] [Related]
29. Detection of MED12 mutations in mesenchymal components of uterine adenomyomas.
Kito M; Maeda D; Kudo-Asabe Y; Tamura D; Makino K; Sageshima M; Nanjo H; Terada Y; Goto A
Hum Pathol; 2021 Mar; 109():31-36. PubMed ID: 33259844
[TBL] [Abstract][Full Text] [Related]
30. HMGA2 and MED12 alterations frequently co-occur in uterine leiomyomas.
Galindo LJ; Hernández-Beeftink T; Salas A; Jung Y; Reyes R; de Oca FM; Hernández M; Almeida TA
Gynecol Oncol; 2018 Sep; 150(3):562-568. PubMed ID: 30017537
[TBL] [Abstract][Full Text] [Related]
31. MED12 mutations and FH inactivation are mutually exclusive in uterine leiomyomas.
Kämpjärvi K; Mäkinen N; Mehine M; Välipakka S; Uimari O; Pitkänen E; Heinonen HR; Heikkinen T; Tolvanen J; Ahtikoski A; Frizzell N; Sarvilinna N; Sjöberg J; Bützow R; Aaltonen LA; Vahteristo P
Br J Cancer; 2016 Jun; 114(12):1405-11. PubMed ID: 27187686
[TBL] [Abstract][Full Text] [Related]
32. Genomics of uterine leiomyomas: insights from high-throughput sequencing.
Mehine M; Mäkinen N; Heinonen HR; Aaltonen LA; Vahteristo P
Fertil Steril; 2014 Sep; 102(3):621-9. PubMed ID: 25106763
[TBL] [Abstract][Full Text] [Related]
33. Factors affecting the loss of MED12-mutated leiomyoma cells during in vitro growth.
Bloch J; Holzmann C; Koczan D; Helmke BM; Bullerdiek J
Oncotarget; 2017 May; 8(21):34762-34772. PubMed ID: 28410233
[TBL] [Abstract][Full Text] [Related]
34. MED12 mutations occurring in benign and malignant mammalian smooth muscle tumors.
Markowski DN; Huhle S; Nimzyk R; Stenman G; Löning T; Bullerdiek J
Genes Chromosomes Cancer; 2013 Mar; 52(3):297-304. PubMed ID: 23225304
[TBL] [Abstract][Full Text] [Related]
35. Clonally related uterine leiomyomas are common and display branched tumor evolution.
Mehine M; Heinonen HR; Sarvilinna N; Pitkänen E; Mäkinen N; Katainen R; Tuupanen S; Bützow R; Sjöberg J; Aaltonen LA
Hum Mol Genet; 2015 Aug; 24(15):4407-16. PubMed ID: 25964426
[TBL] [Abstract][Full Text] [Related]
36. MED12 mutations in human diseases.
Wang H; Shen Q; Ye LH; Ye J
Protein Cell; 2013 Sep; 4(9):643-6. PubMed ID: 23836153
[TBL] [Abstract][Full Text] [Related]
37. Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors.
Mäkinen N; Kämpjärvi K; Frizzell N; Bützow R; Vahteristo P
Mol Cancer; 2017 Jun; 16(1):101. PubMed ID: 28592321
[TBL] [Abstract][Full Text] [Related]
38. Analysis of
Lee M; Cheon K; Chae B; Hwang H; Kim HK; Chung YJ; Song JY; Cho HH; Kim JH; Kim MR
Int J Med Sci; 2018; 15(2):124-128. PubMed ID: 29333096
[TBL] [Abstract][Full Text] [Related]
39. Factors targeting
Bullerdiek J; Rommel B
F1000Res; 2018; 7():359. PubMed ID: 30647905
[TBL] [Abstract][Full Text] [Related]
40. [MED12 gene mutations in women with uterine myoma].
Osinovskaya NS; Ivashchenko TE; Dolinskii AK; Sultanov IY; Ghimbovchi S; Hoffman E; Bezhenar VF; Baranov VS
Genetika; 2013 Dec; 49(12):1426-31. PubMed ID: 25438604
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
